Biggest Challenge of Drug Development in Lymphoma is Enrolling Patients on Clinical Trials

There are currently 1230 clinical trials actively enrolling patients in 1419 worldwide centers. Since January 2009, a total of 437 new lymphoma studies were registered and are currently enrolling patients, of which 238 trials are enrolling patients in the United States.

Dr. Anas Younes is an oncologist, lymphoma expert, and a Professor of Medicine at M. D. Anderson Cancer Center in Houston. He is asking for help in promoting high priority clinical trials that are likely to make an impact on patients’ lives.

“We are now accepting patients with newly diagnosed Hodgkin lymphoma for SGN35 + ABVD study. This novel combination may change the future of therapy for newly diagnosed patients with Hodgkin lymphoma. SGN35 is a targeted monoclonal antibody that preferentially kill the tumor cells. SGN35 has a good single agent activity in heavily pretreated patients with relapsed Hodgkin lymphoma. Please spread the word and help referring patients.”

He is also initiating a discussion regarding why so few cancer patients enroll in clinical trials. Some thoughts? Regional, general oncologists are often not well informed as to appropriate clinical trials and do not typically include discussions of clinical trials in their review of treatment options. Having a fee for service business model and making medicine a business doesn't help either when patients are also customers.

For more information, go to:

http://clinicaltrials.gov/ct2/show/NCT01060904?term=SGN35&rank=8

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap